Daids monitoring for 1 phase III study: A5300B/I2003B (phoenix)
Active Awarded Last action
- Contract number
- 75N93026F00001
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,092,829
Award facts
- Opportunity
-
- 75N93025R00010 Solicitation number
- Contract value 14% obligated
-
- $3,092,829.00 Current, with exercised options
- $21,599,356.00 Potential, with all options
- Completion date 29% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $21.6 million to PPD Development LP for Division of AIDS (DAIDS) monitoring services supporting the Phase III PHOENIX study (A5300B/I2003B). This contract, awarded December 15, 2025, with an ultimate completion date of December 14, 2028, will be performed in Cape Fear, North Carolina. The award utilizes a cost-plus-fixed-fee pricing structure with no set-aside designation and represents a child contract under a larger vehicle arrangement. PPD Development LP, a globally recognized contract research organization and subsidiary of Thermo Fisher Scientific, brings extensive experience in clinical trial management, regulatory support, and research coordination for federal medical research initiatives.
The monitoring services provided under this delivery order support NIAID's critical infectious disease research portfolio. PPD Development LP holds significant federal contract vehicles with NIAID, including a $545 million Comprehensive and Rapid Response contract and a $346 million Early Phase Clinical Trial Units contract, demonstrating the company's established capabilities in clinical trial support and regulatory affairs. The firm's expertise encompasses clinical site monitoring, data management, protocol development, and specialized research support across therapeutic areas—capabilities essential for ensuring the safety, integrity, and regulatory compliance of Phase III clinical studies within the Division of AIDS research program.
Quick answers
Who was awarded contract 75N93026F00001?
75N93026F00001 was awarded to PPD Development LP by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 15, 2025.
How much is contract 75N93026F00001 worth?
The government has obligated $3,092,829 on 75N93026F00001. Its potential value, with all options, is $21,599,356.
Is contract 75N93026F00001 an order under another contract?
Yes. 75N93026F00001 is a delivery order under 75N93021D00035, an indefinite delivery contract.
Was contract 75N93026F00001 competed?
The extent of competition for 75N93026F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award